life technologies corporation
GLASGOW, Scotland, December 16, 2011 -
- University of Strasbourg adopts Life Technologies' SOLiD™ sequencing platform to gain insight into diabetes, obesity, asthma, arterial hypertension and other common diseases.
GLASGOW, Scotland, December 8, 2011 -
Life to provide broader product portfolio to Israeli customers through one distributor.
CARLSBAD, California, September 22, 2011 -
Life to Commercialize Influenza Assay for Use on the 7500 Series of Instruments
Life Technologies Corporation (NASDAQ:LIFE) today announced that the company has signed an agreement with Quidel Corporation to distribute and commercialize molecular diagnostic assays for the European market.
PAISLEY, U.K., June 22, 2011 -
Programme aims to demonstrate
clinical and economic benefit of DNA sequencing such as:
- standardised tests for fast, comprehensive decision making,
and
- increased pharmaceutical investment in UK-based clinical
trials
Life Technologies
Corporation (NASDAQ: LIFE) today announced that the company has
led a successful consortium bidfor a Technology Strategy
Boardgrant, in partnership with the Oxford NIHR Biomedical
Research Centre, AstraZeneca, and Ortho Biotech Oncology Research
& Development unit of Johnson & Johnson Pharmaceutical
Research & Development, L.L.C.
CARLSBAD, California, June 2, 2011 -
- Further analysis on Ion PGM(TM) will confirm data with goal to develop
accurate testing kits to screen samples
Life Technologies Corporation today announced that preliminary data from
DNA sequencing performed in cooperation with the University Hospital
Muenster, Germany, on the Ion Personal Genome Machine (PGM(TM)) strongly
suggests that the bacterium at the root of the deadly outbreak in Germany is
a new hybrid type of pathogenic E.
